Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Cancer Research to Benefit from Development of a Whole-Genome, Cancer-Specific Microarray

By BiotechDaily International staff writers
Posted on 14 Mar 2013
An agreement between a British biotech company and an American-based genomic research consortium paves the way for the development of a whole-genome, cancer-specific microarray.

The biotech company Oxford Gene Technology (Oxford, United Kingdom) will design the microarray for the Cancer Cytogenomics Microarray Consortium (New Orleans, LA, USA). The array will incorporate probes for over 500 cancer genes and 130 cancer-associated genomic regions for hematological and solid tumors. The aim is to improve cancer research through the accurate identification of DNA copy number changes, and loss of heterozygosity associated with different cancer types.

Oxford Gene Technology was chosen following the recent development and commercialization of its CytoSure Haematological Cancer +SNP Array, which targets the four common hematological cancers: chronic lymphocytic leukemia, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndrome.

The CytoSure Haematological Cancer +SNP array combines long oligo array comparative genomic hybridization probes for superior copy number detection with fully research-validated single nucleotide polymorphism (SNP) content for accurate identification of loss of heterozygosity without concurrent changes in gene copy number. The array content has been optimized to target regions known to be important in hematological cancers while providing good backbone coverage. CytoSure Interpret Software, which accompanies all CytoSure arrays, is a powerful, easy-to-use package for the analysis of copy number variation (CNV) and SNP data. Innovative features enable the automation of data analysis workflows, minimizing the need for user intervention and maximizing the consistency and speed of data interpretation.

The Cancer Cytogenomics Microarray Consortium (New Orleans, LA, USA) was formed in August 2009 by a group of clinical cytogeneticists, molecular geneticists, and molecular pathologists, who were interested in applying microarray technologies to cancer diagnosis and cancer research. The mission of the consortium is to promote communication and collaboration among cancer cytogenomics laboratories. The specific goals are to (1) establish platform-neutral and cancer specific microarray designs for diagnostic purposes, (2) share cancer microarray data between participating institutions for education purposes, (3) create a public cancer array database, and (4) carry out multicenter cancer genome translational research. Today, the consortium has grown to include more than 300 members from over 150 organizations in the US, Canada, and in other countries.

“The use of microarray technology will substantially improve the facility of cytogenetics research laboratories to identify cancer,” said Dr. M. Anwar Iqbal, president of the Cancer Cytogenomics Microarray Consortium. “The Cancer Cytogenomics Microarray Consortium board appreciates the efforts of companies such as Oxford Gene Technology to making the Cancer Cytogenomics Microarray Consortium cancer array design available to the cytogenetics research community worldwide.”

Related Links:

Oxford Gene Technology
Cancer Cytogenomics Microarray Consortium



view channel
Image: Schematic representation of HIV DART binding to two distinct antigens simultaneously, redirecting the killer T-cells to destroy HIV-1 infected cells (Photo courtesy of Duke University).

Bi-Specific Antibodies Shown to Clear Latent HIV Infections

Bi-specific antibodies or DARTS (dual-affinity re-targeting proteins) have been used to eliminate latent HIV-infection from patient samples by redirecting polyclonal T-cells to specifically engage with... Read more

Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more


view channel

Sale of Mexican Pharmaceutical Company Expected to Boost Latin American Prescription Drug Market

The sale of a major Mexican pharmaceutical company to an international generic drug corporation is expected to accelerate the growth of the Latin American market for prescription drugs. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) announced that it has entered into definitive agreements to buy Representaciones... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.